Ra Capital Management as of March 31, 2015
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 56 positions in its portfolio as reported in the March 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Sangamo Biosciences (SGMO) | 11.4 | $113M | 7.2M | 15.68 | |
| Achillion Pharmaceuticals | 8.2 | $81M | 8.2M | 9.86 | |
| Dyax | 7.1 | $71M | 4.2M | 16.75 | |
| BioCryst Pharmaceuticals (BCRX) | 6.3 | $63M | 6.9M | 9.03 | |
| Regulus Therapeutics | 6.2 | $61M | 3.6M | 16.94 | |
| Dicerna Pharmaceuticals | 5.9 | $58M | 2.4M | 24.03 | |
| Dynavax Technologies (DVAX) | 5.9 | $58M | 2.6M | 22.43 | |
| Tg Therapeutics (TGTX) | 4.9 | $48M | 3.1M | 15.48 | |
| Coherus Biosciences (CHRS) | 4.8 | $48M | 1.6M | 30.58 | |
| Tekmira Pharmaceuticals Corporation | 4.8 | $47M | 2.7M | 17.46 | |
| Xencor (XNCR) | 3.3 | $33M | 2.1M | 15.32 | |
| Zafgen | 2.9 | $29M | 733k | 39.61 | |
| Bluebird Bio (BLUE) | 2.5 | $24M | 200k | 120.77 | |
| Zs Pharma | 2.4 | $24M | 565k | 42.08 | |
| Ascendis Pharma A S (ASND) | 1.8 | $18M | 1.0M | 17.35 | |
| Juno Therapeutics | 1.7 | $17M | 280k | 60.66 | |
| Omeros Corporation (OMER) | 1.7 | $17M | 749k | 22.03 | |
| Proteon Therapeutics | 1.5 | $15M | 1.3M | 11.63 | |
| Agile Therapeutics | 1.4 | $14M | 1.5M | 9.27 | |
| Novavax | 1.2 | $12M | 1.4M | 8.27 | |
| Therapeuticsmd | 1.0 | $10M | 1.7M | 6.05 | |
| Array BioPharma | 1.0 | $10M | 1.4M | 7.37 | |
| Concert Pharmaceuticals I equity | 1.0 | $10M | 660k | 15.15 | |
| Orexigen Therapeutics | 0.9 | $9.3M | 1.2M | 7.83 | |
| Tenax Therapeutics | 0.9 | $8.7M | 2.7M | 3.26 | |
| Trevena | 0.9 | $8.6M | 1.3M | 6.52 | |
| Sucampo Pharmaceuticals | 0.7 | $7.0M | 450k | 15.56 | |
| Vical Incorporated | 0.7 | $6.6M | 7.0M | 0.94 | |
| Akebia Therapeutics (AKBA) | 0.7 | $6.6M | 597k | 11.11 | |
| Scynexis | 0.7 | $6.5M | 789k | 8.30 | |
| Aurinia Pharmaceuticals (AUPH) | 0.7 | $6.6M | 1.5M | 4.36 | |
| Bellicum Pharma | 0.5 | $5.2M | 225k | 23.17 | |
| Auris Med Hldg | 0.5 | $5.0M | 940k | 5.35 | |
| Versartis | 0.4 | $4.2M | 231k | 18.37 | |
| Trovagene | 0.4 | $4.0M | 594k | 6.81 | |
| Biota Pharmaceuticals | 0.3 | $3.2M | 1.4M | 2.30 | |
| Rockwell Medical Technologies | 0.3 | $2.7M | 250k | 10.93 | |
| T2 Biosystems | 0.2 | $2.1M | 138k | 15.52 | |
| Ocera Therapeutics | 0.2 | $2.0M | 418k | 4.71 | |
| Oncothyreon | 0.2 | $1.9M | 1.2M | 1.63 | |
| Newlink Genetics Corporation | 0.2 | $1.6M | 30k | 54.70 | |
| Agios Pharmaceuticals (AGIO) | 0.2 | $1.7M | 18k | 94.32 | |
| Ptc Therapeutics I (PTCT) | 0.2 | $1.6M | 26k | 60.85 | |
| Repligen Corporation (RGEN) | 0.1 | $1.4M | 45k | 30.36 | |
| Merrimack Pharmaceuticals In | 0.1 | $1.4M | 116k | 11.88 | |
| Tesaro | 0.1 | $1.3M | 24k | 57.40 | |
| Alkermes (ALKS) | 0.1 | $1.2M | 19k | 60.99 | |
| Wafergen Bio-systems | 0.1 | $1.2M | 255k | 4.53 | |
| Regeneron Pharmaceuticals (REGN) | 0.1 | $1.1M | 2.5k | 451.43 | |
| Biogen Idec (BIIB) | 0.1 | $1.1M | 2.6k | 422.31 | |
| Amgen (AMGN) | 0.1 | $943k | 5.9k | 159.83 | |
| Celgene Corporation | 0.1 | $1.0M | 8.7k | 115.29 | |
| ACADIA Pharmaceuticals (ACAD) | 0.1 | $890k | 27k | 32.60 | |
| Keryx Biopharmaceuticals | 0.1 | $754k | 59k | 12.74 | |
| Celladon | 0.1 | $775k | 41k | 18.95 | |
| Puma Biotechnology (PBYI) | 0.1 | $732k | 3.1k | 236.13 |
